MDACC Study No:2009-0447 ( NCT No: NCT01092728)
Title:A Phase II Study of Biological Response to Dasatinib Treatment in Patients with Acral Lentiginous, or Mucosal Melanoma
Principal Investigator:Kevin B. Kim
Treatment Agent:Dasatinib
Study Status:Terminated
Study Description:The goal of this clinical research study is to compare how the drug Sprycel
(dasatinib) can help to control the tumor in patients whose tumor has a gene
abnormality known as a "CKIT mutation" to patients whose tumor does not have a
CKIT mutation. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase II
Treatment Agents:Dasatinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Bristol Myers Squibb
Return Visit:Weekly for 2 wks, 2 wks later, then every 4 wks for up to 12 cycles. Patients
may continue treatment beyond 12 cycles if there is continued clinical response
or disease stabilization per RECIST 1.1 guideline, in the absence of
significant toxicities.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Kevin B. Kim
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults